设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 504|回复: 0

新的CAR-T治疗方式是否会改变ALL疾病的治疗历史?

[复制链接]
发表于 2016-1-29 21:50:41 | 显示全部楼层 |阅读模式
Will novel agents for ALL finally change the natural history?
Pediatric acute lymphoblastic leukemia (ALL) cure rates have markedly improved over the past years to approximately 85%, but remain at 40%-50% in adults. Redefining current adult chemotherapy regimens is likely to improve the natural course of the disease, but new agents are needed. Immunotherapy approaches for pre-B ALL are in the forefront of research on novel agents; in particular, advances are being made in manipulating autologous T cells either by infusion of a bifunctional antibody (eg, blinatumomab) or by ex vivo genetic modification of chimeric antigen receptors (CARs). The natural course of Philadelphia positive ALL has already improved by targeting ABL/BCR1. Other mutated genes are being discovered and novel small molecules that target their products are being studied in clinical trials. Finally, ALL is a heterogeneous disease and novel agents are likely to impact the natural course of smaller populations of biologically defined ALL subtypes.
新的CAR-T治疗方式是否会改变ALL疾病的治疗历史?
儿童急性淋巴细胞白血病(ALL的治愈率在过去几年有显著改善,约85%,但在成年人中仍保持在40%-50%。当前成人化疗方案可能会提高对该病的自然病程,但仍然需要新的药物来治疗。免疫治疗儿童急性淋巴细胞白血病是新型药物研究的前沿,特别是利用一个双功能抗体(如blinatumomab)或者体内基因修饰的嵌合抗原受体(CARs)操作自体T细胞。 费城的一个试验,通过靶向ABL/BCR1治疗ALL疾病的自然进程有所好转。其他一些变异的基因正在被发现,新型的靶向它们的产品正在临床试验中。最后,ALL疾病是一种血液系统疾病,新型药物很可能会影响所有ALL亚型疾病。
出自爱康得生物技术

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-2-23 15:16 , Processed in 0.094775 second(s), 20 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表